Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nilotinib in PH+, BCR-, ABL+ CML Patients (CML0811)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto
ClinicalTrials.gov Identifier:
NCT01535391
First received: February 9, 2012
Last updated: June 13, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2017
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)